von Bueren, André O.

[["dc.bibliographiccitation.firstpage","27"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","35"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Pfaff, Elke"],["dc.contributor.author","El Damaty, Ahmed"],["dc.contributor.author","Balasubramanian, Gnana Prakash"],["dc.contributor.author","Blattner-Johnson, Mirjam"],["dc.contributor.author","Worst, Barbara C."],["dc.contributor.author","Stark, Sebastian"],["dc.contributor.author","Witt, Hendrik"],["dc.contributor.author","Pajtler, Kristian W."],["dc.contributor.author","van Tilburg, Cornelis M."],["dc.contributor.author","Witt, Ruth"],["dc.contributor.author","Milde, Till"],["dc.contributor.author","Jakobs, Martin"],["dc.contributor.author","Fiesel, Petra"],["dc.contributor.author","Frühwald, Michael C."],["dc.contributor.author","Hernáiz Driever, Pablo"],["dc.contributor.author","Thomale, Ulrich W."],["dc.contributor.author","Schuhmann, Martin U."],["dc.contributor.author","Metzler, Markus"],["dc.contributor.author","Bochennek, Konrad"],["dc.contributor.author","Simon, Thorsten"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","von Bueren, André O."],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Herold-Mende, Christel"],["dc.contributor.author","Reuss, David E."],["dc.contributor.author","Kiening, Karl"],["dc.contributor.author","Lichter, Peter"],["dc.contributor.author","Eggert, Angelika"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Jones, David T.W."],["dc.contributor.author","Bächli, Heidi"],["dc.contributor.author","Witt, Olaf"],["dc.date.accessioned","2020-12-10T14:23:39Z"],["dc.date.available","2020-12-10T14:23:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ejca.2019.03.019"],["dc.identifier.issn","0959-8049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72003"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","8"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Krämer, Nadja"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Beilken, Andreas"],["dc.contributor.author","Corbacioglu, Selim"],["dc.contributor.author","Dilloo, Dagmar"],["dc.contributor.author","Hernaiz Driever, Pablo"],["dc.contributor.author","Scheurlen, Wolfram"],["dc.contributor.author","Kulozik, Andreas"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","von Bueren, André"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-10-10T07:47:12Z"],["dc.date.available","2018-10-10T07:47:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing."],["dc.fs.pkfprnr","58469"],["dc.identifier.doi","10.1016/j.ejca.2017.04.023"],["dc.identifier.fs","633320"],["dc.identifier.pmid","28586748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15921"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1879-0852"],["dc.title","Haematological malignancies following temozolomide treatment for paediatric high-grade glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","88"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","89"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Mynarek, Martin"],["dc.contributor.author","von Hoff, Katja"],["dc.contributor.author","Mueller, Klaus"],["dc.contributor.author","Friedrich, Carsten"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Gerber, Nicolas U."],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Warmuth-Metz, Monika"],["dc.contributor.author","Ottensmeier, Holger"],["dc.contributor.author","Kwiecien, Robert"],["dc.contributor.author","Faldum, Andreas"],["dc.contributor.author","Kuehl, Joachim"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Rutkowski, Stefan"],["dc.date.accessioned","2018-11-07T09:39:22Z"],["dc.date.available","2018-11-07T09:39:22Z"],["dc.date.issued","2014"],["dc.identifier.isi","000337924200337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33262"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.eventlocation","Singapore, SINGAPORE"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","INTENSIFICATION OF INDUCTION CHEMOTHERAPY IMPROVES OUTCOMES IN PATIENTS WITH METASTATIC MEDULLOBLASTOMA BELOW 4 YEARS OF AGE: RESULTS OF A PROSPECTIVE, NON-RANDOMIZED PHASE II CLINICAL TRIAL"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2927"],["dc.bibliographiccitation.issue","23"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Zhukova, Nataliya"],["dc.contributor.author","Ramaswamy, Vijay"],["dc.contributor.author","Remke, Marc"],["dc.contributor.author","Pfaff, Elke"],["dc.contributor.author","Shih, David J. H."],["dc.contributor.author","Martin, Dianna C."],["dc.contributor.author","Castelo-Branco, Pedro"],["dc.contributor.author","Baskin, Berivan"],["dc.contributor.author","Ray, Peter N."],["dc.contributor.author","Bouffet, Eric"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Jones, David T. W."],["dc.contributor.author","Northcott, Paul A."],["dc.contributor.author","Kool, Marcel"],["dc.contributor.author","Sturm, Dominik"],["dc.contributor.author","Pugh, Trevor J."],["dc.contributor.author","Pomeroy, Scott L."],["dc.contributor.author","Cho, Yoon-Jae"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Gessi, Marco"],["dc.contributor.author","Rutkowski, Stefan"],["dc.contributor.author","Bognar, Laszlo"],["dc.contributor.author","Klekner, Almos"],["dc.contributor.author","Cho, Byung-Kyu"],["dc.contributor.author","Kim, Seung-Ki"],["dc.contributor.author","Wang, K."],["dc.contributor.author","Eberhart, Charles G."],["dc.contributor.author","Fevre-Montange, Michelle"],["dc.contributor.author","Fouladi, Maryam"],["dc.contributor.author","French, Pim J."],["dc.contributor.author","Kros, Max"],["dc.contributor.author","Grajkowska, Wieslawa A."],["dc.contributor.author","Gupta, Nalin"],["dc.contributor.author","Weiss, William A."],["dc.contributor.author","Hauser, Peter"],["dc.contributor.author","Jabado, Nada"],["dc.contributor.author","Jouvet, Anne"],["dc.contributor.author","Jung, Shin"],["dc.contributor.author","Kumabe, Toshihiro"],["dc.contributor.author","Lach, Boleslaw"],["dc.contributor.author","Leonard, Jeffrey R."],["dc.contributor.author","Rubin, Joshua B."],["dc.contributor.author","Liau, Linda M."],["dc.contributor.author","Massimi, Luca"],["dc.contributor.author","Pollack, Ian F."],["dc.contributor.author","Ra, Young Shin"],["dc.contributor.author","van Meir, Erwin G."],["dc.contributor.author","Zitterbart, Karel"],["dc.contributor.author","Schueller, Ulrich"],["dc.contributor.author","Hill, Rebecca M."],["dc.contributor.author","Lindsey, Janet C."],["dc.contributor.author","Schwalbe, Ed C."],["dc.contributor.author","Bailey, Simon"],["dc.contributor.author","Ellison, David W."],["dc.contributor.author","Hawkins, Cynthia"],["dc.contributor.author","Malkin, David"],["dc.contributor.author","Clifford, Steven C."],["dc.contributor.author","Korshunov, Andrey"],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Taylor, Michael D."],["dc.contributor.author","Tabori, Uri"],["dc.date.accessioned","2018-11-07T09:21:18Z"],["dc.date.available","2018-11-07T09:21:18Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. Patients and Methods We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent cohort of 156 medulloblastomas. Results TP53 mutations are enriched in wingless (WNT; 16%) and sonic hedgehog (SHH; 21%) medulloblastomas and are virtually absent in subgroups 3 and 4 tumors (P < .001). Patients with SHH/TP53 mutant tumors are almost exclusively between ages 5 and 18 years, dramatically different from the general SHH distribution (P < .001). Children with SHH/TP53 mutant tumors harbor 56% germline TP53 mutations, which are not observed in children with WNT/TP53 mutant tumors. Five-year overall survival (OS; +/- SE) was 41% +/- 9% and 81% +/- 5% for patients with SHH medulloblastomas with and without TP53 mutations, respectively (P < .001). Furthermore, TP53 mutations accounted for 72% of deaths in children older than 5 years with SHH medulloblastomas. In contrast, 5-year OS rates were 90% +/- 9% and 97% +/- 3% for patients with WNT tumors with and without TP53 mutations (P = .21). Multivariate analysis revealed that TP53 status was the most important risk factor for SHH medulloblastoma. Survival rates in the validation cohort mimicked the discovery results, revealing that poor survival of TP53 mutations is restricted to patients with SHH medulloblastomas (P = .012) and not WNT tumors. Conclusion Subgroup-specific analysis reconciles prior conflicting publications and confirms that TP53 mutations are enriched among SHH medulloblastomas, in which they portend poor outcome and account for a large proportion of treatment failures in these patients. (C) 2013 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2012.48.5052"],["dc.identifier.isi","000330539300018"],["dc.identifier.pmid","23835706"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29083"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Mynarek, Martin"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Kaatsch, Peter"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Timmermann, Beate"],["dc.contributor.author","Fleischhack, Gudrun"],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Friedrich, Carsten"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Gerber, Nicolas U."],["dc.contributor.author","Mueller, Klaus"],["dc.contributor.author","Tippelt, Stephan"],["dc.contributor.author","Warmuth-Metz, Monika"],["dc.contributor.author","Rutkowski, Stefan"],["dc.contributor.author","von Hoff, Katja"],["dc.date.accessioned","2018-11-07T09:39:18Z"],["dc.date.available","2018-11-07T09:39:18Z"],["dc.date.issued","2014"],["dc.format.extent","22"],["dc.identifier.isi","000337924200082"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33251"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.conference","16th International Symposium on Pediatric Neuro-Oncology (ISPNO)"],["dc.relation.eventlocation","Singapore, SINGAPORE"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","LONG-TERM FOLLOW-UP OF CHILDREN WITH EPENDYMOMA TREATED ACCORDING TO HIT-TRIALS 1987-1998"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","171"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","173"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","von Bueren, André O."],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Fouladi, Maryam"],["dc.contributor.author","van Vuurden, Dannis G."],["dc.contributor.author","van Zanten, Sophie E. M. Veldhuijzen"],["dc.contributor.author","Hoffman, Lindsey M."],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2020-12-10T14:10:26Z"],["dc.date.available","2020-12-10T14:10:26Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00401-018-1863-6"],["dc.identifier.eissn","1432-0533"],["dc.identifier.issn","0001-6322"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70761"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.haserratum","/handle/2/70763"],["dc.title","A suggestion to introduce the diagnosis of “diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","924"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","932"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Gessi, Marco"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Treszl, Andras"],["dc.contributor.author","Muehlen, Anja zur"],["dc.contributor.author","Hartmann, Wolfgang"],["dc.contributor.author","Warmuth-Metz, Monika"],["dc.contributor.author","Rutkowski, Stefan"],["dc.contributor.author","Pietsch, Torsten"],["dc.date.accessioned","2018-11-07T09:38:21Z"],["dc.date.available","2018-11-07T09:38:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are a rare group of neoplasms occurring in the CNS that includes supratentorial CNS-PNETs, medulloepitheliomas, and ependymoblastomas. While ependymoblastomas frequently carry chromosome 19q13.41 amplification and show aggressive clinical behavior, the biological mechanisms and molecular alterations contributing to the pathogenesis of supratentorial CNS-PNETs remain poorly understood. Moreover, genetic alterations suitable for molecular risk stratification are undefined to date. In order to identify possible molecular markers, we performed multiplex ligation-dependent probe amplification (MLPA) and molecular inversion probe (MIP) analysis on DNA samples of 25 supratentorial CNS-PNETs (median age, 5.35 years; range, 2.41-17.28 years). Tumors with ependymoblastic rosettes (ependymoblastoma/ETANTR) and LIN28A positivity were excluded. MLPA and MIP analysis revealed large losses of genomic material of chromosomes 3, 4, 5, and 13, while frequent gains affected chromosomes 1, 17, 19, 20, and 22. High copy number gains (amplifications) were found in particular at chromosomes 2p24.3 (MYCN, n = 6 cases) and 4q12 (n = 2 cases). Patients with tumors harboring 2p gain or MYCN amplification showed unfavorable overall survival (P = .003 and P = .001, respectively).These markers were independent of the presence of metastases, which was indeed a clinical factor associated with poor overall survival (P = .01) in this series. In the era of the personalized neuro-oncology, the identification of these molecular prognostic markers associated with patient outcome may represent a significant step towards improved patient stratification and risk-adapted therapeutic strategies for patients suffering from supratentorial CNS-PNETs."],["dc.identifier.doi","10.1093/neuonc/not302"],["dc.identifier.isi","000338126100004"],["dc.identifier.pmid","24470553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33048"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Mackay, Alan"],["dc.contributor.author","Burford, Anna"],["dc.contributor.author","Salom, Janat Fazal"],["dc.contributor.author","Bjerke, Lynn"],["dc.contributor.author","Vinci, Mara"],["dc.contributor.author","Molinari, Valeria"],["dc.contributor.author","Taylor, Kathryn"],["dc.contributor.author","Nandhabalan, Meera"],["dc.contributor.author","Popov, Sergey"],["dc.contributor.author","Mu, Kun"],["dc.contributor.author","Trabelsi, Saoussen"],["dc.contributor.author","H'mida-Ben Brahim, Dorra"],["dc.contributor.author","Reis, Rui M. G."],["dc.contributor.author","Moore, Andrew"],["dc.contributor.author","Ng, Ho-Keung"],["dc.contributor.author","von Bueren, Andre"],["dc.contributor.author","Baudis, Michael"],["dc.contributor.author","Jones, Chris"],["dc.date.accessioned","2018-11-07T10:13:09Z"],["dc.date.available","2018-11-07T10:13:09Z"],["dc.date.issued","2016"],["dc.format.extent","70"],["dc.identifier.isi","000379749000270"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40371"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.conference","17th International Symposium on Pediatric Neuro-Oncology (ISPNO)"],["dc.relation.eventlocation","Liverpool, ENGLAND"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","INTEGRATED MOLECULAR META-ANALYSIS OF 1000 PAEDIATRIC HIGH GRADE GLIOMA AND DIPG"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","12"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","13"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Mackay, Alan"],["dc.contributor.author","Vinci, Mara"],["dc.contributor.author","Burford, Anna"],["dc.contributor.author","Bjerke, Lynn"],["dc.contributor.author","Taylor, Katy"],["dc.contributor.author","Nandhabalan, Meera"],["dc.contributor.author","Marshall, Lynley"],["dc.contributor.author","Molinari, Valeria"],["dc.contributor.author","Popov, Sergey"],["dc.contributor.author","Ingram, Wendy"],["dc.contributor.author","Moore, Andrew"],["dc.contributor.author","Trabelsi, Saoussen"],["dc.contributor.author","Hmida, Dorra"],["dc.contributor.author","Mu, Kun"],["dc.contributor.author","Bidinotto, Lucas"],["dc.contributor.author","Reis, Rui M. G."],["dc.contributor.author","Ng, H. K."],["dc.contributor.author","von Bueren, Andre"],["dc.contributor.author","Baudis, Michael"],["dc.contributor.author","Jones, Chris"],["dc.date.accessioned","2018-11-07T09:56:12Z"],["dc.date.available","2018-11-07T09:56:12Z"],["dc.date.issued","2015"],["dc.identifier.isi","000361304800049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36910"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.conference","3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","INTEGRATIVE MOLECULAR META-ANALYSIS OF 700 PEDIATRIC HIGH GRADE GLIOMA AND DIPG DEFINES WIDESPREAD INTER-AND INTRA-TUMORAL HETEROGENEITY"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","189"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.bibliographiccitation.lastpage","191"],["dc.bibliographiccitation.volume","129"],["dc.contributor.author","von Bueren, Andre Oscar"],["dc.contributor.author","Seidel, Clemens"],["dc.contributor.author","Friedrich, Carsten"],["dc.date.accessioned","2018-11-07T10:11:05Z"],["dc.date.available","2018-11-07T10:11:05Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1007/s11060-016-2159-0"],["dc.identifier.isi","000381152000022"],["dc.identifier.pmid","27278608"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39977"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-7373"],["dc.relation.issn","0167-594X"],["dc.title","Comment on: Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]